Program
CHO cell
Also written as “Recombinant new coronavirus vaccine (CHO cell) group”, “Recombinant Zoster Vaccine (CHO Cell)” and “Recombinant two-component COVID-19 vaccine (CHO cell)”.
Its studies are mostly in COVID-19 · Herpes Zoster · Coronavirus Infections · Kidney Failure, Chronic, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Products | 121 open or running | phase 4since Mar 28, 2022 | Jun 16, 2020 | none ahead |
| Jiangsu Rec-Biotechnology | 50 open or running | phase 3since May 30, 2022 | Mar 19, 2021 | none ahead |
| MAXVAX Biotechnology Limited Liability | 54 open or running | phase 3since Jun 2, 2024 | Jun 2, 2024 | Dec 31, 2027phase 3 · NCT07293065 |
| 3SBio | 20 open or running | phase 3since Jan 13, 2022 | May 10, 2019 | none ahead |
| Guangzhou Patronus Biotech | 20 open or running | phase 3since Dec 23, 2022 | Dec 23, 2022 | none ahead |
| Sinopharm | 20 open or running | phase 2since Apr 24, 2021 | Apr 24, 2021 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | phase 2since Oct 19, 2026 | Oct 19, 2026 | Jul 31, 2027phase 2 · NCT07892989 |
Also a collaborator on its studies: yantai-patronus-biotech-co-ltd and iqvia-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since May 10, 2019.
- Nov 1, 20212 phase 3 studies in COVID-19Chongqing Zhifei Biological Products · NCT05107375, NCT05128643
- Nov 4, 2021Phase 2 study in COVID-19Chongqing Zhifei Biological Products · NCT05109598 · 400 enrolled · China
- Jan 13, 2022Phase 3 study in Kidney Failure, Chronic3SBio · NCT05211167 · 300 enrolled · China
- Mar 28, 2022Phase 4 study in COVID-19Chongqing Zhifei Biological Products · NCT05890521 · 100,000 planned · China
- Apr 11, 2022Phase 2 study in COVID-19Jiangsu Rec-Biotechnology · NCT05323435 · 300 enrolled · United Arab Emirates
- May 30, 2022Phase 3 study in COVID-19Jiangsu Rec-Biotechnology · NCT05398848 · 7,623 enrolled · Nepal, Russian Federation
- Oct 10, 2022No phase study in COVID-19Chongqing Zhifei Biological Products · NCT05574985 · 272 enrolled · China
- Dec 23, 2022Guangzhou Patronus Biotech's first studies: 2 phase 3 studies in COVID-19New to Guangzhou Patronus BiotechGuangzhou Patronus Biotech · NCT05664932, NCT05683600
- Jan 27, 2023Phase 1 study in Herpes ZosterJiangsu Rec-Biotechnology · NCT05769049 · 48 enrolled · Philippines
- Jun 2, 2024MAXVAX Biotechnology Limited Liability's first study: phase 3 study in Herpes ZosterNew to MAXVAX Biotechnology Limited LiabilityMAXVAX Biotechnology Limited Liability · NCT06447779 · 25,000 enrolled · China
- Oct 22, 2024Phase 3 study in Herpes ZosterMAXVAX Biotechnology Limited Liability · NCT06654700 · 1,200 enrolled · China
- Nov 14, 20252 phase 3 studiesMAXVAX Biotechnology Limited Liability · NCT07272434, NCT07293065
- May 25, 2026No phase study in Respiratory Syncytial Virus (RSV)MAXVAX Biotechnology Limited Liability · NCT07618325 · 60 planned
- Oct 19, 2026CSPC Pharmaceutical Group's first study: phase 2 study in Herpes ZosterNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07892989 · 496 planned
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Herpes ZosterCSPC Pharmaceutical Group · NCT07892989
- Dec 31, 2027Primary completion: phase 3 study in Herpes ZosterMAXVAX Biotechnology Limited Liability · NCT07293065
- Jun 30, 2028Primary completion: no phase study in Respiratory Syncytial Virus (RSV)MAXVAX Biotechnology Limited Liability · NCT07618325
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07892989Herpes Zoster | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 31, 2027 | 496 |
| NCT07618325Respiratory Syncytial Virus (RSV) | – | Not yet recruiting | MAXVAX Biotechnology Limited Liability | Jun 30, 2028 | 60 |
| NCT07293065Herpes Zoster · China | 3 | Active, not recruiting | MAXVAX Biotechnology Limited Liability | Dec 31, 2027 | 12,000 |
| NCT07272434Respiratory Syncytial Virus (RSV) · China | 3 | Recruiting | MAXVAX Biotechnology Limited Liability | Jul 31, 2026 | 25,000 |
| NCT06654700Herpes Zoster · China | 3 | Completed | MAXVAX Biotechnology Limited Liability | May 9, 2025 | 1,200 |
| NCT06447779Herpes Zoster · China | 3 | Active, not recruiting | MAXVAX Biotechnology Limited Liability | Mar 29, 2026 | 25,000 |
| NCT05769049Herpes Zoster · Philippines | 1 | Completed | Jiangsu Rec-Biotechnology | Dec 6, 2023 | 48 |
| NCT05683600COVID-19 · China | 3 | Terminated | Guangzhou Patronus Biotech | Jul 12, 2023 | 3,000 |
| NCT05664932COVID-19 · China | 3 | UNKNOWN | Guangzhou Patronus Biotech | Jan 18, 2023 | 1,200 |
| NCT05574985COVID-19 · China | – | Completed | Chongqing Zhifei Biological Products | Oct 9, 2022 | 272 |
| NCT05398848COVID-19 · Nepal, Russian Federation | 3 | Completed | Jiangsu Rec-Biotechnology | Sep 4, 2023 | 7,623 |
| NCT05323435COVID-19 · United Arab Emirates | 2 | Completed | Jiangsu Rec-Biotechnology | Jul 5, 2022 | 300 |
| NCT05890521COVID-19 · China | 4 | Recruiting | Chongqing Zhifei Biological Products | Jun 16, 2022 | 100,000 |
| NCT05211167Kidney Failure, Chronic · China | 3 | UNKNOWN | 3SBio | Jun 30, 2023 | 300 |
| NCT05128643COVID-19 · China | 3 | UNKNOWN | Chongqing Zhifei Biological Products | Apr 12, 2022 | 300 |
| NCT05109598COVID-19 · China | 2 | Completed | Chongqing Zhifei Biological Products | Feb 14, 2022 | 400 |
| NCT05107375COVID-19 · China | 3 | Completed | Chongqing Zhifei Biological Products | Mar 4, 2022 | 299 |
| NCT05084989COVID-19 · Philippines | 2 | Completed | Jiangsu Rec-Biotechnology | Aug 18, 2022 | 948 |
| NCT05091411COVID-19 · China | 3 | UNKNOWN | Chongqing Zhifei Biological Products | Nov 2021 | 1,680 |
| NCT05089045COVID-19 · China | – | Completed | Chongqing Zhifei Biological Products | Sep 16, 2021 | 360 |
| NCT05033847Coronavirus Infections · United Arab Emirates | 2 | UNKNOWN | Sinopharm | Nov 2023 | 1,800 |
| NCT04961359Coronavirus Infections · China | 1 | Completed | Chongqing Zhifei Biological Products | Dec 12, 2021 | 75 |
| NCT04869592COVID-19 · China | 2 | Completed | Sinopharm | Aug 29, 2023 | 3,100 |
| NCT04818801COVID-19 · New Zealand | Early 1 | Completed | Jiangsu Rec-Biotechnology | May 5, 2022 | 100 |
| NCT04646590Prevention of COVID-19 · China, Ecuador, Indonesia and more | 3 | UNKNOWN | Chongqing Zhifei Biological Products | Nov 28, 2021 | 28,904 |
| NCT04550351Coronavirus Infections · China | 1 | UNKNOWN | Chongqing Zhifei Biological Products | Dec 18, 2020 | 50 |
| NCT04466085Coronavirus Infections · China | 2 | UNKNOWN | Chongqing Zhifei Biological Products | Oct 22, 2020 | 900 |
| NCT04445194Coronavirus Infections · China | 1 | UNKNOWN | Chongqing Zhifei Biological Products | Oct 22, 2020 | 50 |
| NCT03950687Chronic Renal Failure With Hemodialysis · China | 2 | UNKNOWN | 3SBio | Jun 30, 2020 | 150 |
How it is read
Names in the registry
- “Recombinant new coronavirus vaccine (CHO cell) group”, 5 entries
- “Recombinant Zoster Vaccine (CHO Cell)”, 3 entries
- “Recombinant two-component COVID-19 vaccine (CHO cell)”, 3 entries
- “Recombinant RSV Vaccine (CHO Cell)”, 2 entries
- “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)”, 2 entries
Conditions, from the studies’ own filings
- COVID-19, 16 studies
- Herpes Zoster, 5 studies
- Coronavirus Infections, 4 studies
- Kidney Failure, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.